Detalhe da pesquisa
1.
Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.
Dermatol Ther
; 34(5): e15067, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34302318
2.
Time-varying pattern of recurrence risk for localized melanoma in China.
World J Surg Oncol
; 18(1): 6, 2020 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31901239
3.
Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
J Cancer Res Clin Oncol
; 149(2): 701-708, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454283
4.
Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Front Pharmacol
; 14: 1064227, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762107
5.
Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
Int J Biol Sci
; 19(6): 1846-1860, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37063431
6.
Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Sci Rep
; 12(1): 9559, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688842
7.
Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
J Cancer Res Clin Oncol
; 148(5): 1159-1169, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34181096
8.
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Front Immunol
; 13: 902167, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36003385
9.
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
J Immunother Cancer
; 8(2)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33158915